Dextech Medical AB engages in the provision of research and development of drug candidates for urological oncology. It focuses on the treatment of prostate cancer and non-malignant diseases. Its product portfolio includes OsteoDex, SomaDex, CatDex, and PSMADex. The company was founded by Anders R. Holmberg and Sten Nilsson on April 21, 2004 and is headquartered in Uppsala, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company